Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead Coming To The End Of HCV Road With Triple-Drug Regimen

Executive Summary

Gilead reported an expected and continued sales decline in HCV – an area in which the company soon will be done with R&D, since unmet needs have been filled or will be soon by drug regimens from Gilead and its competitors. The company is hunting new assets, but taking a disciplined approach on price and quality.

Advertisement

Related Content

Gilead Completes HCV Clinical Development With Vosevi Approval
Gilead's CEO Gives Glimpse Of Strategic Opportunities As HCV Sales Slide Continues
Gilead Offers Split Guidance For HCV; Expects Further Decline In 2017
Gilead Plays Up Its Strength As Market Awaits Business Development Moves
Keeping Track: New Submissions In Bladder Cancer, HCV And Diabetes; Avastin Label Expands
3Q Pharma Results Preview: Pfizer, Gilead, Allergan, Valeant, AstraZeneca
Gilead Sees Prospects For Declining HCV Revenues To Stabilize
When Will Gilead Make Its M&A Move?
Filgotinib Progress At Higher Dose Justifies Gilead's Gamble
Galapagos Soothed By Gilead's $725m Up Front For AbbVie Reject Filgotinib

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097593

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel